The co-expression of PD1, CTLA4, LAG3, and TIM3 were more commonly observed in tumor tissues compared with normal tissues, which may explain the limited effects of a single immune checkpoint inhibitor and the use of combined strategies. This evidence concerns the gene CTLA4 and neoplasm.